JW Asset Management LLC Lowers Position in Establishment Labs Holdings Inc. $ESTA

JW Asset Management LLC lowered its stake in Establishment Labs Holdings Inc. (NASDAQ:ESTA) by 12.0% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 2,692,856 shares of the company’s stock after selling 368,838 shares during the quarter. Establishment Labs accounts for 72.6% of JW Asset Management LLC’s portfolio, making the stock its largest position. JW Asset Management LLC owned about 0.09% of Establishment Labs worth $231,074,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also added to or reduced their stakes in the company. KBC Group NV bought a new position in shares of Establishment Labs during the 1st quarter valued at $28,000. Quarry LP purchased a new position in shares of Establishment Labs in the 3rd quarter worth $34,000. Northwestern Mutual Wealth Management Co. bought a new stake in shares of Establishment Labs in the second quarter worth $43,000. Kestra Advisory Services LLC bought a new stake in shares of Establishment Labs in the fourth quarter worth $47,000. Finally, Osaic Holdings Inc. increased its position in Establishment Labs by 900.0% during the second quarter. Osaic Holdings Inc. now owns 2,000 shares of the company’s stock valued at $85,000 after acquiring an additional 1,800 shares during the last quarter. Institutional investors own 72.91% of the company’s stock.

Establishment Labs Stock Performance

NASDAQ:ESTA traded up $1.00 during mid-day trading on Tuesday, hitting $75.29. 433,849 shares of the company traded hands, compared to its average volume of 540,089. The company has a quick ratio of 2.52, a current ratio of 3.84 and a debt-to-equity ratio of 12.11. The stock’s fifty day moving average price is $83.19 and its 200-day moving average price is $74.89. The firm has a market cap of $2.24 billion, a price-to-earnings ratio of -57.47 and a beta of 1.05. Establishment Labs Holdings Inc. has a one year low of $36.53 and a one year high of $97.59.

Establishment Labs (NASDAQ:ESTA) last posted its quarterly earnings data on Thursday, August 6th. The company reported ($0.39) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.05). The company had revenue of $67.54 million for the quarter, compared to analysts’ expectations of $65.79 million. Establishment Labs had a negative net margin of 15.82% and a negative return on equity of 196.69%. The firm’s quarterly revenue was up 31.7% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.57) earnings per share. Research analysts anticipate that Establishment Labs Holdings Inc. will post -1.15 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts have issued reports on the company. Canaccord Genuity Group set a $105.00 target price on Establishment Labs in a research report on Thursday, August 6th. Citigroup raised shares of Establishment Labs from a “neutral” rating to a “buy” rating and set a $92.00 price target for the company in a research report on Thursday, August 13th. JPMorgan Chase & Co. raised their price objective on shares of Establishment Labs from $84.00 to $95.00 and gave the stock an “overweight” rating in a report on Friday, August 7th. Weiss Ratings restated a “sell (e+)” rating on shares of Establishment Labs in a research report on Wednesday, June 24th. Finally, Needham & Company LLC upped their target price on shares of Establishment Labs from $86.00 to $95.00 and gave the company a “buy” rating in a report on Thursday, August 6th. Eight investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $100.25.

Establishment Labs Company Profile

Establishment Labs Holdings Inc is a global medical technology company specializing in the design, development and manufacture of silicone gel breast implants for aesthetic and reconstructive surgery. The company’s proprietary portfolio is built around patient-focused safety, customization and innovation, offering solutions intended to enhance surgical outcomes and support clinical traceability.

The company’s flagship products fall under the Motiva® brand, which includes a range of ergonomic and round breast implants featuring SilkSurface® texturing and an embedded Q Inside® Safety microtransponder for unique implant identification.